Gastrointestinal Symptoms Partnering 2007-2013

Keywords : biotech

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service. The Gastrointestinal Symptoms Partnering 2007-2013 report provides understanding and access to the gastrointestinal symptoms partnering deals and agreements entered into by the worlds leading healthcare companies. •Trends in gastrointesti...

More »

Please note: this report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible.

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

The Gastrointestinal Symptoms Partnering 2007-2013 report provides understanding and access to the gastrointestinal symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.


•Trends in gastrointestinal symptoms partnering deals
•Top gastrointestinal symptoms deals by value
•Deals listed by company A-Z, industry sector, stage of development, technology type



The Gastrointestinal Symptoms Partnering 2007-2013 provides understanding and access to the gastrointestinal symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.



The report provides an analysis of gastrointestinal symptoms partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors gastrointestinal symptoms technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.



Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.



This data driven report contains over 100 links to online copies of actual gastrointestinal symptoms deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.



The initial chapters of this report provide an orientation of gastrointestinal symptoms partnering trends.



Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in gastrointestinal symptoms partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.



Chapter 3 provides an overview of the leading gastrointestinal symptoms deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.



Chapter 4 provides a comprehensive directory of gastrointestinal symptoms partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.



In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of gastrointestinal symptoms technologies and products.



Report scope



Gastrointestinal Symptoms Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to gastrointestinal symptoms trends and structure of deals entered into by leading companies worldwide.



This data driven report includes:


•Trends in gastrointestinal symptoms dealmaking in the biopharma industry since 2007
•Access to summary headline, upfront, milestone and royalty data
•Access to over 100 gastrointestinal symptoms contract documents
•The leading gastrointestinal symptoms deals by value since 2007



In Gastrointestinal Symptoms Partnering 2007-2013, the available deals are listed by:


•Headline value
•Upfront payment value
•Royalty rate value
•Company A-Z
•Industry sector
•Stage of development at signing
•Deal component type
•Technology type



Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Gastrointestinal Symptoms Partnering 2007-2013 provides the reader with the following key benefits:


•In-depth understanding of allergy deal trends since 2007
•Access to summary headline, upfront, milestone and royalty data
•Comprehensive access to over 100 actual allergy deals entered into by the world’s biopharma companies since 2007
•Insight into key deal terms included in contracts, where disclosed
•Understand the key deal terms companies have agreed in deals
•Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Biotechnology Industry

Executive Summary



Chapter 1 – Introduction



Chapter 2 – Trends in gastrointestinal symptoms partnering


•2.1. Introduction
•2.2. Gastrointestinal symptoms partnering over the years
•2.3. Bigpharma gastrointestinal symptoms dealmaking activity
•2.4. Gastrointestinal symptoms partnering by deal type
•2.5. Gastrointestinal symptoms partnering industry sector
•2.6. Gastrointestinal symptoms partnering by stage of development
•2.7. Gastrointestinal symptoms partnering by technology type
•2.8. Disclosed financial deal terms for gastrointestinal symptoms partnering
•2.8.1 Gastrointestinal symptoms headline values
•2.8.2 Gastrointestinal symptoms upfront payments
•2.8.3 Gastrointestinal symptoms milestone payments
•2.8.4 Gastrointestinal symptoms royalty rates



Chapter 3 – Leading gastrointestinal symptoms deals


•3.1. Introduction
•3.2. Top gastrointestinal symptoms deals by value
•3.3. Top gastrointestinal symptoms deals involving bigpharma



Chapter 4 – Dealmaking directory


•4.1. Introduction
•4.2. Company A-Z
•4.3. By deal type
•Asset purchase
•Bigpharma outlicensing
•Co-development
•Collaborative R&D
•Co-market
•Contract service
•Co-promotion
•CRADA
•Cross-licensing
•Development
•Distribution
•Equity purchase
•Evaluation
•Grant
•Joint venture
•Licensing
•Manufacturing
•Marketing
•Option
•Promotion
•Research
•Settlement
•Spin out
•Sub-license
•Supply
•Termination
•4.4. By industry sector
•Academic
•Bigpharma
•Biotech
•Drug delivery
•Medical device
•Diagnostic
•Generic pharma
•Government
•Non-profit
•Pharmaceutical
•Research tools
•Services
•Specialty pharma
•4.5. By stage of development
•Discovery
•Pre-clinical
•Phase I
•Phase II
•Phase III
•Registration
•Marketed
•4.6. By technology type
•Analysis
•Animal models
•Assays
•Bioinformatics
•Biological compounds
•Biomarkers
•Biomaterials
•Cell culture
•Cell therapy
•Clinical testing
•Diagnostic - companion
•Devices
•Diagnostics
•Discovery tools
•DNA probes
•Drug delivery
•Enabling technology
•Epigenetics
•Equipment
•Facilities
•Gene therapy
•Genomics
•Imaging
•Industrial chemicals
•In vitro models
•Monoclonal antibodies
•Nanotechnology
•Oligonucleotide
•Peptides
•Personalised medicine
•Processes
•Proteomics
•Radio/Chemo-therapy
•Recombinant DNA
•Research services
•Research supplies
•RNA therapeutics
•Screening
•Small molecules
•Stem cells
•Vaccines



Chapter 5 – Partnering resource center


•5.1. Online partnering
•5.2. Partnering events
•5.3. Further reading on dealmaking



Appendices


•Appendix 1 – Deal type definitions



About Wildwood Ventures


•Current Partnering
•Current Agreements
•Recent titles from CurrentPartnering
•Order Form – Reports



TABLE OF FIGURES


•Figure 1: gastrointestinal symptoms partnering since 2007
•Figure 2: Bigpharma – top 50 – gastrointestinal symptoms deals 2007 to 2011
•Figure 3: Bigpharma gastrointestinal symptoms deal frequency – 2007 to 2011
•Figure 4: Gastrointestinal symptoms partnering by deal type since 2007
•Figure 5: Gastrointestinal symptoms partnering by industry sector since 2007
•Figure 6: Gastrointestinal symptoms partnering by stage of development since 2007
•Figure 7: Gastrointestinal symptoms partnering by technology type since 2007
•Figure 8: Gastrointestinal symptoms deals with a headline value
•Figure 9: Gastrointestinal symptoms deals with upfront payment values
•Figure 10: Gastrointestinal symptoms deals with milestone payments
•Figure 11: Gastrointestinal symptoms deals with royalty rates, %
•Figure 12: Top gastrointestinal symptoms deals by value since 2007
•Figure 13: Top gastrointestinal symptoms deals signed by bigpharma value since 2007
•Figure 14: Online partnering resources
•Figure 15: Forthcoming partnering events
•Figure 16: Deal type definitions